Aravive Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Aravive.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth27.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Apr 26
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Sep 03
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Aravive Q2 GAAP EPS misses, revenue beats

Aug 11

Aravive appoints Robert Geller as CMO

Jul 05

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

May 15
We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Nov 06
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Jun 25
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive EPS beats by $0.01, misses on revenue

May 06

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18
Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aravive has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqGS:ARAV - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20237-40-59-59N/A
6/30/20239-77-69-69N/A
3/31/202310-113-70-70N/A
12/31/20229-76-65-65N/A
9/30/20229-60-59-59N/A
6/30/20226-56-49-49N/A
3/31/20228-44-35-35N/A
12/31/20217-39-32-32N/A
9/30/202112-30-20-20N/A
6/30/202110-30-17-17N/A
3/31/20216-28-18-18N/A
12/31/20206-31-12-12N/A
9/30/2020N/A-31-21-21N/A
6/30/2020N/A-26-19-19N/A
3/31/20203-24-20-20N/A
12/31/20195-18-17-17N/A
9/30/20196-65-21-21N/A
6/30/20196-65-23-23N/A
3/31/20193-72-23-23N/A
12/31/20181-76-29-29N/A
9/30/2018406-58-57N/A
6/30/201840-37-78-75N/A
3/31/201840-64-94-90N/A
12/31/201740-85-121-116N/A
9/30/2017N/A-138-101-98N/A
6/30/2017N/A-116N/A-53N/A
3/31/2017N/A-101N/A-54N/A
12/31/2016N/A-96N/A-41N/A
9/30/2016N/A-94N/A-38N/A
6/30/2016N/A-87N/A-78N/A
3/31/2016N/A-84N/A-70N/A
12/31/2015N/A-82N/A-69N/A
9/30/2015N/A-78N/A-64N/A
6/30/2015N/A-71N/A-58N/A
3/31/2015N/A-60N/A-54N/A
12/31/2014N/A-83N/A-40N/A
9/30/2014N/A-73N/A-33N/A
6/30/2014N/A-64N/A-27N/A
3/31/2014N/A-59N/A-18N/A
12/31/2013N/A-18N/A-17N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ARAV's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if ARAV's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ARAV's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ARAV's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ARAV's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ARAV's Return on Equity is forecast to be high in 3 years time


Discover growth companies